Published in Breast Cancer Res Treat on December 14, 2014
The protective effect of longer duration of breastfeeding against pregnancy-associated triple negative breast cancer. Oncotarget (2016) 0.75
Clinicopathologic Characteristics of Pregnancy-Associated Breast Cancer: Results of Analysis of a Nationwide Breast Cancer Registry Database. J Breast Cancer (2017) 0.75
CARPEL FACTORY, a Dicer homolog, and HEN1, a novel protein, act in microRNA metabolism in Arabidopsis thaliana. Curr Biol (2002) 15.13
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Methylation as a crucial step in plant microRNA biogenesis. Science (2005) 7.16
Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem (2006) 3.74
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 3.47
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst (2008) 2.94
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol (2011) 2.58
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer (2014) 2.20
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol (2005) 2.20
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res (2009) 1.77
The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol (2012) 1.77
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids (2007) 1.75
Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res (2008) 1.64
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer (2010) 1.62
The Cancer Genetics Network: recruitment results and pilot studies. Community Genet (2003) 1.61
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol (2011) 1.51
Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol (2006) 1.51
Breast cancer in Brazil: present status and future goals. Lancet Oncol (2012) 1.49
Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat (2009) 1.49
The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res (2002) 1.49
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr (2002) 1.48
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood (2013) 1.48
Two RNA binding proteins, HEN4 and HUA1, act in the processing of AGAMOUS pre-mRNA in Arabidopsis thaliana. Dev Cell (2003) 1.47
Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival. Leuk Lymphoma (2012) 1.46
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis (2012) 1.45
Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.45
Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol (2005) 1.44
Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma (2011) 1.44
DICER-LIKE2 plays a primary role in transitive silencing of transgenes in Arabidopsis. PLoS One (2008) 1.43
Lapatinib: current status and future directions in breast cancer. Oncologist (2006) 1.43
Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat (2008) 1.40
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol (2008) 1.39
Mammographic breast density and race. AJR Am J Roentgenol (2007) 1.35
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist (2008) 1.32
Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates. J Biol Chem (2010) 1.32
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res (2013) 1.30
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res (2007) 1.29
Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet (2012) 1.28
Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res (2010) 1.27
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast (2013) 1.24
Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res (2006) 1.24
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat (2008) 1.23
Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol (2012) 1.19
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst (2013) 1.19
Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol (2011) 1.19
An all-metallic logic gate based on current-driven domain wall motion. Nat Nanotechnol (2008) 1.19
Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat (2004) 1.18
Lapatinib-associated toxicity and practical management recommendations. Oncologist (2007) 1.17
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene (2004) 1.12
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat (2007) 1.10
Immunohistochemical characterization and functional identification of mammary gland telocytes in the self-assembly of reconstituted breast cancer tissue in vitro. J Cell Mol Med (2012) 1.10
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer (2008) 1.10
Women's responses to changes in U.S. Preventive Task Force's mammography screening guidelines: results of focus groups with ethnically diverse women. BMC Public Health (2013) 1.10
Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? J Clin Oncol (2014) 1.09
Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat (2009) 1.08
Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res (2005) 1.07
Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome. J Neurotrauma (2002) 1.07
Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. Carcinogenesis (2013) 1.07
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat (2009) 1.06
Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. PLoS Genet (2011) 1.06
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genet Epidemiol (2011) 1.06
The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials (2012) 1.05
PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem (2009) 1.05
MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res (2013) 1.05
Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res (2007) 1.05
Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol (2009) 1.04
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem (2012) 1.03
Single cell optical imaging and spectroscopy. Chem Rev (2013) 1.03
The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Res Treat (2011) 1.02
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol (2012) 1.02
Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol (2010) 1.02
TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer (2007) 1.01
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res (2006) 1.01
Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest (2006) 1.01
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast (2007) 1.00
Identification of the functional role of AF1Q in the progression of breast cancer. Breast Cancer Res Treat (2007) 1.00
The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol (2006) 1.00
RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat (2010) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. Cancer Sci (2012) 0.98
Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet (2009) 0.98
The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer. Breast Cancer Res Treat (2014) 0.98
Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab (2012) 0.97
Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J Cereb Blood Flow Metab (2003) 0.97